Should I buy or sell dormakaba stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for dormakaba in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DRRKF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DRRKF, but not buy additional shares or sell existing shares. View DRRKF analyst ratings or view top-rated stocks .

How have DRRKF shares performed in 2024?

dormakaba's stock was trading at $383.2350 at the beginning of the year. Since then, DRRKF shares have increased by 24.5% and is now trading at $477.00. View the best growth stocks for 2024 here .

Are investors shorting dormakaba?

dormakaba saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,300 shares, an increase of 32.0% from the March 15th total of 2,500 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days. View dormakaba's Short Interest .

How do I buy shares of dormakaba?

Shares of DRRKF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:DRRKF

dormakaba (DRRKF) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free DRRKF Stock Alerts

$477.00

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $477.00
▼
$477.00
50-Day Range: $477.00
▼
$477.00
52-Week Range: $477.00
▼
$477.00

Volume: N/A
Average Volume: 100 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Short Interest

Get dormakaba alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About dormakaba Stock (OTCMKTS:DRRKF)

dormakaba Holding AG provides access and security solutions worldwide. It offers door hardware products, such as door closer systems, door locks, and escape route systems; and entrance systems, including sliding, revolving, swing doors, as well as sensor barriers and speed and self-boarding gates. The company also provides electronic access and data that include access readers, terminals, electronic fittings, and locking cylinders; mechanical cylinder lock and master key systems; lodging systems comprising electronic door locks, and perimeter and facility readers, as well as mobile access solutions; safe locks; movable walls; and key blanks and key cutting machines under the Silca, Ilco, and Advanced Diagnostics brand names. In addition, it offers maintenance, repair, spare parts, installation, and consulting services. The company serves airports, banking and insurance, education, government and administration, healthcare, hospitality, industry and manufacturing, offices, residential, retail, sports and culture, transport and logistic, and utility sectors. dormakaba Holding AG was founded in 1862 and is headquartered in Rumlang, Switzerland.

DRRKF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DRRKF Stock News Headlines

April 15, 2024 | americanbankingnews.com

dormakaba Holding AG (OTCMKTS:DRRKF) Short Interest Update

December 6, 2023 | realmoney.thestreet.com

Dormakaba just downgraded at Jefferies, here's why

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

January 7, 2022 | nasdaq.com

dormakaba Holding AG Registered Shares - Class B (DRRKF)

See More Headlines

Receive DRRKF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for dormakaba and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Industrials
Industry: Security & Protection Services
Sub-Industry: N/A
Current Symbol: OTCMKTS:DRRKF
CUSIP: N/A
CIK: N/A
Web: www.dormakaba.com
Phone: 41 44 818 90 11
Fax: N/A
Employees: 15,272
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Till Reuter (Age 56)
Chief Executive Officer
Ms. Christina Johansson (Age 58)
Chief Financial Officer
Dr. Andreas Haberli (Age 56)
Chief Technology Officer
Dr. Siegfried Schwirzer
Head of Investor Relations
Mr. David Ratcliffe
General Counsel
Mr. Stefano Zocca (Age 61)
President Key & Wall Solutions
Mr. Stephen Bewick (Age 58)
President Region Europe & Africa
Mr. Alex Housten (Age 44)
President Region Americas
Magin Guardiola
Chief Innovation Officer

Key Competitors

View All Competitors

DRRKF Stock Analysis - Frequently Asked Questions

Should I buy or sell dormakaba stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for dormakaba in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DRRKF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DRRKF, but not buy additional shares or sell existing shares.
View DRRKF analyst ratings or view top-rated stocks.
How have DRRKF shares performed in 2024?: dormakaba's stock was trading at $383.2350 at the beginning of the year. Since then, DRRKF shares have increased by 24.5% and is now trading at $477.00.
View the best growth stocks for 2024 here.
Are investors shorting dormakaba?: dormakaba saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,300 shares, an increase of 32.0% from the March 15th total of 2,500 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.
View dormakaba's Short Interest.
How do I buy shares of dormakaba?: Shares of DRRKF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:DRRKF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial